Objective: We assessed clinical effectiveness, longevity of treatment effects, and patient satisfaction with incobotulinumtoxinA for glabellar frown lines (GFL) treatment in Asian patients.
by Gabriele F. Muti, MD, and Matteo Basso, MD Dr. Muti is with the Department of Plastic Surgery, European Dermatological Institute, in Milan, Italy. Dr. Basso is with the Studio Dermatologico in Rome, Italy. Funding: No funding was provided for this study. Disclosures: Dr. Muti has been an investigator and speaker for Merz Pharmaceuticals GmbH